153 related articles for article (PubMed ID: 38751436)
1. Pyrotinib is effective in both trastuzumab-sensitive and primary resistant HER2-positive breast tumors.
Zhang J; Yin G; Ye C; Feng M; Ji C; Zhou W; Wang F; Yu L; Huang S; Yu Z
Chin J Cancer Res; 2024 Apr; 36(2):124-137. PubMed ID: 38751436
[TBL] [Abstract][Full Text] [Related]
2. Clinical observation of neoadjuvant chemotherapy with pyrotinib plus trastuzumab in HER2-positive breast cancer: a cohort study.
Li Q; Wang Y; Zhu M; Gu Y; Tang Y
Gland Surg; 2021 Dec; 10(12):3389-3402. PubMed ID: 35070899
[TBL] [Abstract][Full Text] [Related]
3. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
Gao Z; Xu J; Wang Y; Wu J; Sun T
Front Oncol; 2021; 11():715554. PubMed ID: 34722261
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of trastuzumab and albumin-bound paclitaxel with or without pyrotinib as neoadjuvant therapy for HER2-positive breast cancer: a prospective observational cohort study.
Wang Y; Xu Y; Liu X; Li C; Wang J; Zhang X; Shao B; Zhang J
Gland Surg; 2024 May; 13(5):654-662. PubMed ID: 38845840
[TBL] [Abstract][Full Text] [Related]
6. Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial.
Cao J; Teng Y; Li H; Zhang L; Ouyang Q; Xie W; Pan Y; Song Z; Ling X; Wu X; Xu J; Li L; Ren L; Wang H; Zhou D; Luo J; Hu X
BMC Med; 2023 Aug; 21(1):300. PubMed ID: 37559142
[TBL] [Abstract][Full Text] [Related]
7. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib-Containing Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer: A Multicenter Retrospective Analysis.
Mao X; Lv P; Gong Y; Wu X; Tang P; Wang S; Zhang D; You W; Wang O; Zhou J; Li J; Jin F
Front Oncol; 2022; 12():855512. PubMed ID: 35463365
[TBL] [Abstract][Full Text] [Related]
9. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
10. HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials.
Li X; Wu S; Zhang L; Zhu J; Xu B
Ann Transl Med; 2020 Dec; 8(24):1634. PubMed ID: 33490146
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
[TBL] [Abstract][Full Text] [Related]
12. Protocol for pyrotinib cardiac safety in patients with HER2-positive early or locally advanced breast cancer-The EARLY-MYO-BC study.
Chai Y; Jiang M; Wang Y; Liu Q; Lu Q; Tao Z; Wu Q; Yin W; Lu J; Pu J
Front Cardiovasc Med; 2023; 10():1021937. PubMed ID: 36844736
[TBL] [Abstract][Full Text] [Related]
13. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.
You S; Xie Y; Sang D; Luo T; Yuan P; Xu F; Wang B
Front Endocrinol (Lausanne); 2023; 14():1325540. PubMed ID: 38149099
[TBL] [Abstract][Full Text] [Related]
14. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
[TBL] [Abstract][Full Text] [Related]
15. Pyrotinib and Trastuzumab Plus Chemotherapy Serve as an Acceptable Neoadjuvant Regimen Exhibiting Good Efficacy and Tolerance in HER2-Positive Breast Cancer Patients.
Chen Y; Zhang T; Zhang R; Cao X
Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38527247
[No Abstract] [Full Text] [Related]
16. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
17. Retrospective Analysis of Pyrotinib-Based Therapy for Metastatic Breast Cancer: Promising Efficacy in Combination with Trastuzumab.
Gu Q; Zhu M; Wang Y; Gu Y
Breast Cancer (Dove Med Press); 2024; 16():253-268. PubMed ID: 38812479
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
Jiang K; Hong R; Xia W; Lu Q; Li L; Huang J; Shi Y; Yuan Z; Zheng Q; An X; Xue C; Huang J; Bi X; Chen M; Zhang J; Xu F; Wang S
Cancer Res Treat; 2024 Apr; 56(2):513-521. PubMed ID: 37846468
[TBL] [Abstract][Full Text] [Related]
20. Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial.
Xie XF; Zhang QY; Huang JY; Chen LP; Lan XF; Bai X; Song L; Xiong SL; Guo SJ; Du CW
Breast Cancer Res Treat; 2023 Jan; 197(1):93-101. PubMed ID: 36309908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]